EUVIMEDEUVIMED entdecken
Klinische Studie (Phase I)Randomisierte kontrollierte StudieKlinische Studie (Phase III)Open Access · CC BY 4.0

Population Pharmacokinetics and Pharmacodynamics of Depemokimab in People with Asthma and Chronic Rhinosinusitis with Nasal Polyps

Anders Thorsted iD, Lénaïg Tanneau, Alexandra Lavalley-Morelle, Richard Follows, Loretta Jacques, Nicholas Bird iD, Philippe Gevaert iD, Ian Pavord, Jakob Ribbing, Anubha Gupta, Peter Howarth, Stein Schalkwijk

The Journal of Clinical Pharmacology · 2026

DOI: 10.1002/jcph.70187 ↗

Kurz gefasst

Klinische Studie (Phase I) in der Zeitschrift The Journal of Clinical Pharmacology, 2026. Verfasst von Anders Thorsted und 11 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Pharmacology Modelling and Simulation, GSK, Solna, Sweden. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Asthma, Nasal Polyps, Rhinosinusitis. Die Arbeit nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: GSK, GlaxoSmithKline.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Depemokimab is the first ultra‐long‐acting biologic with enhanced interleukin‐5 (IL‐5) binding affinity, high potency, and extended half‐life, enabling twice‐yearly dosing. Depemokimab has demonstrated efficacy and safety in patients with asthma and chronic rhinosinusitis with nasal polyps. These analyses aimed to characterize the pharmacokinetic/pharmacodynamic (PK/PD) profile of depemokimab. Data from three Phase I studies (NCT03287310/NCT05140200/NCT05602025) and four Phase III studies (SWIFT‐1/‐2: NCT04719832/NCT04718103; ANCHOR‐1/‐2: NCT05274750/NCT05281523) were used to develop a PK model for depemokimab and PK/PD model for blood eosinophil count (BEC) reduction, a key biomarker of type 2 inflammation. Participants received subcutaneous depemokimab or placebo (one dose in Phase I [2‐300 mg in NCT03287310; 100 mg or 300 mg in NCT05140200/NCT05602025] and two 100 mg doses in Phase III) and ≥1 post‐first‐dose PK/PD (BEC) observation. PK analysis included 961 participants and PK/PD analysis included 1324 participants. Predicted geometric mean half‐life was 47 days, with negligible accumulation in PK. Depemokimab 100 mg rapidly reduced BEC to

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, Monoclonal, HumanizedAsthmaNasal PolypsRhinosinusitisAdolescentAdultAgedFemaleHumansMaleMiddle AgedYoung AdultChronic DiseaseDouble-Blind MethodEosinophilsHalf-LifeInterleukin-5Models, Biological

Stichwörter der Autor:innen

NONMEMbiologicalsmodeling and simulationpharmacokinetic‐pharmacodynamicpopulation analysis

Substanzen

Antibodies, Monoclonal, HumanizedInterleukin-5depemokimab

Autor:innen und Institutionen

  • Clinical Pharmacology Modelling and Simulation, GSK, Solna, Sweden.
  • Pharmetheus AB, Uppsala, Sweden.
  • Clinical Research, Respiratory, Inflammation and Immunology Research Unit (RIIRU), GSK, London, UK.
  • Biostatistics, GSK, London, UK.
  • Upper Airways Research Laboratory, Department of Head and Skin, Ghent University, Ghent, Belgium.
  • Oxford Respiratory NIHR Biomedical Research Centre, Nuffield Department of Clinical Medicine, University of Oxford, Oxford, UK.

ORCID-Profile: Anders Thorsted, Nicholas Bird, Philippe Gevaert

Förderung

  • GSK
  • GlaxoSmithKline

Zitieren

APA

Thorsted, A., Tanneau, L., Lavalley-Morelle, A., Follows, R., Jacques, L., Bird, N., Gevaert, P., Pavord, I., Ribbing, J., Gupta, A., Howarth, P., & Schalkwijk, S. (2026). Population Pharmacokinetics and Pharmacodynamics of Depemokimab in People with Asthma and Chronic Rhinosinusitis with Nasal Polyps. The Journal of Clinical Pharmacology. https://doi.org/10.1002/jcph.70187

Vancouver

Thorsted A, Tanneau L, Lavalley-Morelle A, Follows R, Jacques L, Bird N, et al. Population Pharmacokinetics and Pharmacodynamics of Depemokimab in People with Asthma and Chronic Rhinosinusitis with Nasal Polyps. The Journal of Clinical Pharmacology. 2026. doi:10.1002/jcph.70187

BibTeX
@article{Thorsted2026,
  author = {Thorsted, Anders and Tanneau, Lénaïg and Lavalley-Morelle, Alexandra and Follows, Richard and Jacques, Loretta and Bird, Nicholas and Gevaert, Philippe and Pavord, Ian and Ribbing, Jakob and Gupta, Anubha and Howarth, Peter and Schalkwijk, Stein},
  title = {Population Pharmacokinetics and Pharmacodynamics of Depemokimab in People with Asthma and Chronic Rhinosinusitis with Nasal Polyps},
  journal = {The Journal of Clinical Pharmacology},
  year = {2026},
  doi = {10.1002/jcph.70187}
}
Kostenlos starten →